Related Experiment Videos
Esthesioneuroblastoma: prognosis and management
A Morita1, M J Ebersold, K D Olsen
1Department of Neurologic Surgery, Mayo Clinic, Rochester, Minnesota.
Neurosurgery
|May 1, 1993
Summary
Esthesioneuroblastoma treatment outcomes show a 69% 5-year survival rate. Tumor grade significantly impacts prognosis, with low-grade tumors having an 80% survival rate compared to 40% for high-grade tumors.
Area of Science:
- Oncology
- Head and Neck Surgery
Background:
- Esthesioneuroblastoma is a rare malignancy of the sinonasal tract.
- Treatment strategies and prognostic factors require further elucidation.
Purpose of the Study:
- To review clinical manifestations and treatment outcomes of esthesioneuroblastoma patients.
- To identify significant prognostic factors influencing survival and recurrence.
Main Methods:
- Retrospective review of 49 patients treated between 1951 and 1990.
- Analysis of clinical data, treatment modalities, and survival rates.
Main Results:
- Overall 5-year survival was 69%; tumor progression occurred in 51% of patients.
- Pathological grade was the most significant prognostic factor: 80% survival for low-grade vs. 40% for high-grade (P=0.0001).
- Recurrence and regional metastasis necessitate aggressive treatment; craniofacial resection is the current standard surgical approach.
Conclusions:
- Tumor grade is a critical determinant of esthesioneuroblastoma prognosis.
- Multimodal treatment including surgery, radiation, and potentially chemotherapy is essential.
- Long-term follow-up is crucial due to the possibility of late recurrences.